Chronic verubecestat treatment suppresses amyloid accumulation in advanced aged Tg2576-AβPPswe mice without inducing microhemorrhage

Journal of Alzheimer's Disease

Volumn 59, Issue 4, 2017, Pages 1393-1413

  Villarreal, Stephanie ^a,d   Zhao, Fuqiang ^a   Hyde, Lynn A ^b   Holder, Daniel ^a   Forest, Thomas ^a   Sondey, Marie ^b,e   Chen, Xia ^b,f   Sur, Cyrille ^a   Parker, Eric M ^b   Kennedy, Matthew E ^c,g  

^a MRL   (United States)

^b Structural Chemistry Department   (United States)

^c MRL Boston   (United States)

^d Project Management Merck and Co Inc   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f NONE   (United States)

^g NONE   (United States)

Author keywords

Alzheimer's disease; amyloid ; ARIA; BACE; beta secretase; disease modification; inhibitor; microhemorrhage; MRI; prodromal Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; COLLAGEN TYPE 4; THIOFLAVINE; VERUBECESTAT; AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY; NEUROLEPTIC AGENT; PRESENILIN 1; SULFOXIDE; THIADIAZINE DERIVATIVE;

AGED; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN CORTEX; CAPILLARY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; HIPPOCAMPUS; HISTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; LONG TERM CARE; MICROHEMORRHAGE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEREOMETRY; TG2576 MOUSE; TREATMENT DURATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; BLOOD; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE MODEL; GENETICS; HUMAN; LONGITUDINAL STUDY; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPSYCHOTIC AGENTS; COLLAGEN TYPE IV; CYCLIC S-OXIDES; DISEASE MODELS, ANIMAL; HUMANS; INTRACRANIAL HEMORRHAGES; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; MUTATION; PLAQUE, AMYLOID; PRESENILIN-1; THIADIAZINES;

EID: 85027524974     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170056     Document Type: Article

References (36)

1. Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf M, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn H, Kuvelkar R, Li W, Mattson B, Mei H, Palcza J, Scott JD, Tanen M, Troyer M, Tseng J, Parker EM, Stone J, Forman M. (2016). Discovery of Verubecestat (MK-8931), a BACE1 inhibitor that dramatically reduces CNS A levels in Alzheimer's disease patients. Sci Transl Med 8, 363ra150
2. Hardy J, Selkoe DJ. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356
3. Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8, 595-608
4. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. (2011). Autosomal-dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 3, 1
5. Barao S, Moechars D, Lichtenthaler SF, De Strooper B. (2016). BACE1 Physiological functions may limit its use as therapeutic target for Alzheimer's disease. Trends Neurosci 39, 158-169
6. Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF. (2014). Function, therapeutic potential and cell biology ofBACE proteases: Current status and future prospects. J Neurochem 130, 4-28
7. Karran E, Hardy J. (2014). A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 76, 185-205
8. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial, Investigators. (2009). Aphase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070
9. Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melançon D, Morris K, Ketter N, Liu E, Brashear HR. (2016). Amyloid-related imaging abnormalitieshaemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: A historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry 87, 106-112
10. Piazza F, Winblad B. (2016). Amyloid-Related Imaging Abnormalities (ARIA) in immunotherapy trials for Alzheimer's disease: Need for prognostic biomarkers? J Alzheimers Dis 52, 417-420
11. Briggs R, Kennelly SP, O'Neill D. (2016). Drug treatments in Alzheimer's disease. Clin Med (Lond) 16, 247-253
12. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. (2011). Amyloidrelated imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7, 367-385
13. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919
14. Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG. (2013). Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement 9, S105-S115
15. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. (2012). Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69, 1430-1440
16. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. (2002). Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298, 1379
17. Wilcock D, Rojiani A, Rosenthal A, Subbarao S, Freeman M, Gordon M, Morgan D. (2004). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1, 24
18. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. (2005). Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25, 629-636
19. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ. (2012). An effector-reduced antibeta-amyloid (Abeta) antibody with unique Abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32, 9677-9689
20. Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, Hillen H, Ebert U, Severin JM, Cox BF, Llano DA, Day M, Fox GB. (2010). Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. J Pharmacol Exp Ther 335, 580-588
21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102
22. Beckmann N, Gérard C, Abramowski D, Cannet C, Staufenbiel M. (2011). Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: Application to passive Abeta immunotherapy. J Neurosci 31, 1023-1031
23. Dobrowolska JA, Michener MS, Wu G, Patterson BW, Chott R, Ovod V, Pyatkivskyy Y, Wildsmith KR, Kasten T, Mathers P, Dancho M, Lennox C, Smith BE, Gilberto D, McLoughlin D, Holder DJ, Stamford AW, Yarasheski KE, Kennedy ME, Savage MJ, Bateman RJ. (2014). CNS amyloid-, soluble APP-and -kinetics during BACE inhibition. J Neurosci 34, 8336-8346
24. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM, Microbleed Study, Group. (2009). Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol 8, 165-174
25. Madsen K, Holmskov U. (1995). Capillary density measurements in skeletal muscle using immunohistochemical staining with anti-collagen type IV antibodies. Eur J Appl Physiol Occup Physiol 71, 472-474
26. Cebasek V, Kubínová L, Ribarič S, Erzen I. (2004). A novel staining method for quantification and 3D visualisation of capillaries and muscle fibres. Eur J Histochem 48, 151-158
27. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, Games D. (2008). Immunotherapy reduces vascular amyloid beta in PDAPP mice. J Neurosci 28, 6787-6793
28. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. (2004). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24, 6144-6151
29. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. (2004). Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15, 11-20
30. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. (2006). Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26, 5340-5346
31. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D. (2006). Intracranial administration of deglycosylated C-terminalspecific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloiddepositing transgenic mice. J Neuroinflammation 3, 11
32. Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, Marks MS, De Strooper B, Raposo G, van Niel G. (2013). BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci USA 110, 10658-10663
33. Shimshek DR, Jacobson LH, Kolly C, Zamurovic N, Balavenkatraman KK, Morawiec L, Kreutzer R, Schelle J, Jucker M, Bertschi B, Theil D, Heier A, Bigot K, Beltz K, Machauer R, Brzak I, Perrot L, Neumann U. (2016). Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice. Sci Rep 6, 21917
34. van Maanen EM, van Steeg TJ, Michener MS, Savage MJ, Kennedy ME, Kleijn HJ, Stone JA, Danhof M. (2016). Systems pharmacology analysis of the amyloid cascade after-secretase inhibition enables the identification of an A 42 oligomer pool. J Pharmacol Exp Ther 357, 205-216
35. Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, Pautler RG, Taffet GE, Zheng H. (2014). Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: Interplay with cerebral blood flow. Mol Neurodegener 9, 1326-1329
36. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. (2016). The antibody aducanumab reduces A plaques in Alzheimer's disease. Nature 537, 50-56